Table 1.
Baseline characteristics of patients with advanced non-squamous NSCLS receiving carboplatinum and paclitaxel (CP) or carboplatinum, paclitaxel, bevacizumab (CPB)
| CP, Pre Matched | CP, Post Matched | CPB, Pre Matched | CPB, Post Matched | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | ASI (n=273) | Other (n=1192) | p-value | ASI (n=255) | Other (n=255) | p-value | ASI (n=78) | Othern= (270) | p-value | ASI (n=61) | Other (n=61) | p-value |
| Demographics, N (%) | ||||||||||||
| Age at diagnosis, Mean (std) | 68 (8) | 62 (10) | < 0.01 | 67 (8) | 67 (9) | 0.76 | 63 (8) | 59 (11) | < 0.01 | 62 (8) | 62 (11) | 0.93 |
| Non-White | 90 (33) | 381 (32) | 0.75 | 83 (33) | 77(30) | 0.63 | 23 (30) | 91 (34) | 0.75 | 18 (30) | 14 (23) | 0.40 |
| Male | 139 (51) | 621 (52) | 0.72 | 129 (51) | 128 (50) | 0.66 | 38 (49) | 134 (50) | 0.72 | 27 (44) | 29 (47) | 0.99 |
| Poor/Undifferentiated/Unk Tumor Grade | 55 (71) | 225 (83) | 0.01 | 223 (87) | 222 (87) | 0.99 | 55 (71) | 225 (83) | 0.01 | 44 (72) | 49 (80) | 0.09 |
| Education | 0.01 | 0.91 | 0.60 | 0.22 | ||||||||
| Rank 1, lowest | 61 (22) | 202 (17) | 54 (21) | 29 (11) | 18 (23) | 48 (18) | 7 (11) | 7 (11) | ||||
| Rank 2 | 46 (17) | 241 (20) | 44 (17) | 45 (18) | 10 (13) | 41 (15) | 11 (18) | 22 (36) | ||||
| Rank 3 | 46 (17) | 252 (21) | 45 (18) | 47 (18) | 14 (18) | 62 (23) | 14 (23) | 9 (15) | ||||
| Rank 4 | 73 (27) | 242 (20) | 68 (27) | 70 (27) | 18 (23) | 49 (18) | 14 (23) | 14 (23) | ||||
| Rank 5, highest | 47 (17) | 255 (21) | 44 (17) | 46 (18) | 18 (23) | 70 (26) | 15 (25) | 9 (15) | ||||
| Risk Factors | ||||||||||||
| COPD | 111 (41) | 315 (26) | 0.27 | 135 (53) | 137 (54) | 0.72 | 25 (32) | 124 (46) | 0.57 | 25 (41) | 29 (48) | 0.36 |
| Cardiovascular Disease1 | 124 (45) | 253 (21) | < 0.01 | 108 (42) | 109 (43) | 0.86 | 25 (32) | 38 (14) | < 0.01 | 15 (25) | 17(28) | 0.99 |
| Peripheral Vascular Disease | 88 (32) | 172 (14) | < 0.01 | 74 (29) | 81 (32) | 0.77 | 21 (27) | 26 (10) | < 0.01 | 19 (31) | 11 (18) | 0.06 |
| Diabetes | 111 (41) | 141 (12) | < 0.01 | 93 (36) | 94 (37) | 0.71 | 27 (35) | 16 (6) | < 0.01 | 14 (23) | 14 (23) | 0.83 |
| Other Disease2 | 111 (41) | 315 (26) | < 0.01 | 101 (40) | 106 (42) | 0.52 | 41 (53) | 68 (25) | < 0.01 | 30 (49) | 15 (25) | < 0.01 |
| Health Plan | 0.03 | 0.67 | 0.10 | 0.18 | ||||||||
| Site(s) 2 | 119 (44) | 432 (36) | 107 (42) | 99 (39) | 40 (51) | 106 (39) | 29 (48) | 32 (54) | ||||
| Site(s) 3 | 43 (16) | 173 (15) | 40 (16) | 40 (16) | 11 (14) | 62 (23) | 9 (15) | 11 (18) | ||||
| Other HTN Med | 126 (46) | 320 (27) | < 0.01 | 112 (44) | 108 (42) | 0.59 | 55 (71) | 86 (32) | 27 (44) | 26 (43) | 0.72 | |
| Smoking Status | 0.78 | 0.86 | 0.21 | 0.83 | ||||||||
| Ever | 177 (65) | 748 (63) | 167 (65) | 163 (64) | 54 (69) | 163 (60) | 44 (72) | 38 (62) | ||||
| Never | 40 (15) | 192 (16) | 37 (15) | 37 (15) | 13 (17) | 71 (26) | 10 (16) | 13 (21) | ||||
| Unknown | 56 (21) | 252 (21) | 51 (20) | 55 (22) | 11 (14) | 36 (33) | 7 (11) | 10 (16) | ||||
| Weight Change 6 mos prior to Ca Diagnosis | 0.12 | 0.72 | 0.44 | 0.97 | ||||||||
| > 6% weight loss | 56 (21) | 205 (17) | 52 (20) | 49 (19) | 16 (21) | 40 (15) | 12 (20) | 12 (20) | ||||
| <= 6% weight loss or weight gain | 128 (47) | 522 (44) | 119 (47) | 117 (46) | 40 (51) | 141 952) | 32 (52) | 30 (49) | ||||
| Unknown/Missing | 89 (33) | 465 (39) | 84 (33) | 89 (35) | 22 (28) | 89 (33) | 17 (28) | 19 (31) | ||||
| Hypertension Meds | NA | NA | NA | NA | ||||||||
| ACEI | 210 (77) | -- | -- | 199 (78) | -- | -- | 55 (71) | -- | -- | 45 (74) | -- | -- |
| ARB | 63 (23) | -- | -- | 56 (22) | -- | -- | 23 (29) | -- | -- | 16 (26) | -- | -- |
1
Cardiovascular Disease includes diagnoses of cardiovascular disease, congestive heart failure and myocardial infarction
2
Other Disease includes liver disease, plegia, renal disease, peptic ulcer disease, and rheumatic disease